Precision biosciences stock.

With Precision Biosciences stock trading at $0.41 per share, the total value of Precision Biosciences stock (market capitalization) is $49.24M. Precision Biosciences stock was originally listed at a price of $17.44 in Mar 28, 2019. If you had invested in Precision Biosciences stock at $17.44, your return over the last 4 years would have been ...Precision BioSciences, Inc. Common Stock (DTIL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Justin Zelin’s Buy rating for the Precision BioSciences stock is based on several factors. The company, which primarily focuses on in-vivo gene editing, is heading towards advancing its ARCUS ...Precision BioSciences’ shares were up almost 30% on Jan 19 following the IND acceptance. In fact, shares of the company have gained 37% in the past year compared to the industry ’s 11.1% increase.

November 28, 2023. DURHAM, N.C. -- (BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,...Jun 21, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately ... If you are looking for stocks with good return, Precision Biosciences Inc stock can be a bad, high-risk 1-year investment option. Precision Biosciences Inc real time quote is equal to 0.363 USD at 2023-12-03, but your current investment may be devalued in the future.

May 9, 2023 · The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.

Precision BioSciences’ shares were up almost 30% on Jan 19 following the IND acceptance. In fact, shares of the company have gained 37% in the past year compared to the industry ’s 11.1% increase.View Precision BioSciences, Inc DTIL investment & stock information. Get the latest Precision BioSciences, Inc DTIL detailed stock quotes, stock data, Real …Justin Zelin’s Buy rating for the Precision BioSciences stock is based on several factors. The company, which primarily focuses on in-vivo gene editing, is heading towards advancing its ARCUS ...Nov 30, 2023 · The stock of Precision Biosciences Inc (NASDAQ: DTIL) has decreased by -9.31 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -11.84% in its stock price over the last five trading days. Business Wire reported 2023-10-23 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing […] Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing …

Nov 7, 2023 · Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to ...

8 thg 3, 2019 ... Precision BioSciences Stock Offered in IPO · Unwanted on- and off-target DNA modifications. · Inability to efficiently and precisely introduce ...

Precision Biosciences Stock Earnings. The value each DTIL share was expected to gain vs. the value that each DTIL share actually gained. Precision Biosciences ( DTIL) reported Q3 2023 earnings per share (EPS) of -$0.14, beating estimates of -$0.18 by 21.37%. In the same quarter last year, Precision Biosciences 's earnings per share (EPS) was ...Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Get a real-time Precision BioSciences, Inc. (DTIL) stock price quote with breaking news, financials, statistics, charts and more.About Precision BioSciences, Inc. ... risks related to ownership of our common stock and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10 ...DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately ...

Jul 24, 2023 · Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Find out why I rate DTIL stock a Buy. precisionbiosciences .com. Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. [3] Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform. [4] We would like to show you a description here but the site won’t allow us.Precision BioSciences (Nasdaq: DTIL) has a different way to edit genes, without CRISPR. It's not a new way... It's the old way. While CRISPR technology was first described in 2012, the first experiments to discover Precision Bio's method – called meganucleases – were done in the 1970s.Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments.Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update. November 7, 2023 at 7:00 AM EST. PDF Version ... Weighted average shares of common stock outstanding-basic and diluted 115,174,752 110,849,196 Precision Biosciences, Inc. Condensed Balance Sheets Data ...precisionbiosciences .com. Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. [3] Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform. [4]

May 31, 2023 · In a report released today, Justin Zelin from BTIG maintained a Buy rating on Precision BioSciences ( DTIL – Research Report ), with a price target of $6.00. The company’s shares opened today ...

Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ...Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Precision BioSciences ( DTIL – Research Report) today and set a price target of $17.00. The company’s shares opened today at ...Nov 1, 2023 · Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. DelveInsight’s, “Refractory Multiple Myeloma Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in …We would like to show you a description here but the site won’t allow us.DTIL (Precision BioSciences Inc.): A Small Biotech Company with Fluctuating Earnings and Revenue Growth. DTIL (Precision BioSciences Inc.) is a biotechnology company that specializes in gene editing and gene therapy. On September 12, 2023, the stock opened at $0.41, slightly lower than the previous day’s closing price …Stock Quote. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High. 52 Week Low.Based on short-term price targets offered by five analysts, the average price target for Precision BioSciences comes to $3.00. The forecasts range from a low of $1.00 to a high of $5.00. The ...

The Precision BioSciences Inc. stock price fell by -9.31% on the last day (Wednesday, 29th Nov 2023) from $0.408 to $0.370. During the last trading day the stock fluctuated 15.44% from a day low at $0.360 to a day high of $0.416. The price has risen in 6 of the last 10 days and is up by 6.78% over the past 2 weeks.

Institutional Ownership and Shareholders. Precision Biosciences Inc (US:DTIL) has 116 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 49,734,624 shares. Largest shareholders include Great Point Partners Llc, Capital World …

Track Precision Biosciences Inc (DTIL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsOverall, Precision BioSciences Inc stock has a Value Grade of C, Growth Grade of C, Quality Grade of D, Momentum Grade of F Earnings Estimate Revisions Grade of C. Whether or not you should buy Precision BioSciences Inc stock will ultimately depend on your individual goals, risk tolerance and allocation.Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update. March 15, 2022 at 7:00 AM EDT. ... Weighted average shares of common stock outstanding - basic and diluted 58,688,102 52,031,740 Precision Biosciences, Inc. Consolidated Balance Sheets Data ...The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.View Precision BioSciences, Inc DTIL investment & stock information. Get the latest Precision BioSciences, Inc DTIL detailed stock quotes, stock data, Real …Valuation metrics show that Precision BioSciences, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of ...DURHAM, N.C. -- (BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary …Dec 1, 2023 · The latest price target for Precision BioSciences ( NASDAQ: DTIL) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 3.00 expecting DTIL to ... Precision BioSciences stock soars premarket on R&D collaboration and license pact with Novartis SA News Wed, Jun. 22, 2022 4 Comments. Precision BioSciences to sell ~36M shares for gross proceeds ...Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.

Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Tuesday, April 18, 2023. Precision Biosciences Expects Approximately $158M In Cash And Cash Equivalents As Of March 31, 2023. The Company's Management Also Believes That The Existing Cash And Cash ...ARCUS is a precise and versatile genome editing technology discovered and developed by scientists at Precision BioSciences. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases to insert (knock in), remove (knock out), or repair DNA of living cells and tissues.Instagram:https://instagram. when to buy a putarcher aviation stockstwilio stokvgsh dividend yield Precision BioSciences (DTIL) JonesTrading analyst Soumit Roy reiterated a Buy rating on Precision BioSciences today and set a price target of $4.00. The company’s shares closed last Wednesday at ...DURHAM, N.C.-June 21, 2022 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with … lsyixfidelity day trade Precision BioSciences, Inc. Common Stock (DTIL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. workers compensation companies in florida 7 ngày trước ... DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ...The stock option was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee to commence service with Precision. The stock option …At the core of Precision Biosciences’ groundbreaking research is the ARCUS genome editing technology. This cutting-edge technology possesses unparalleled precision and versatility, enabling scientists to insert, delete, or repair disease-causing DNA in a wide range of genetic disorders. With the potential to revolutionize the field of genetic ...